文献速递类风湿关节炎

绝经期激素治疗与血清阳性类风湿关节炎风险:韩国全国性队列研究

Menopausal hormone therapy and risk of seropositive rheumatoid arthritis: A nationwide cohort study in Korea.
PubMed 文献 · Semin Arthritis Rheum · 2023-10-13

该回顾性队列研究基于韩国全国人群数据,纳入2011年至2014年间因绝经就诊的40岁以上女性,经倾向评分匹配后比较绝经期激素治疗(MHT)组与非MHT组各138,991对,随访至2020年。结果显示MHT组血清阳性类风湿关节炎风险较对照组未显著升高(HR 1.12,95%CI 0.998-1.256),但使用MHT≤3年及特定药物(雌孕激素、替勃龙)与风险升高相关。

要点

  • MHT整体未显著增加血清阳性RA风险(HR 1.12,95%CI 0.998-1.256)。
  • 使用MHT≤3年与RA风险升高相关(HR 1.277,95%CI 1.127-1.447)。
  • 雌孕激素HR 1.24(95%CI 1.05-1.46),替勃龙HR 1.33(95%CI 1.13-1.57)。

核心结论

  • MHT使用对绝经后女性类风湿关节炎的发生未显示显著影响。
  • 亚组分析显示MHT使用最初3年内类风湿关节炎风险有值得注意的升高。

研究设计与样本

  • 韩国全国性回顾性队列研究,纳入2011年1月1日至2014年12月31日因绝经就诊的40岁以上女性452,124例。
  • 经倾向评分匹配后,MHT组与非MHT组各纳入138,991对,随访至2020年12月31日。
  • 类风湿关节炎按国际疾病分类第10版定义,限于血清阳性类风湿关节炎(M05)。

主要发现

  • MHT组138,424例患者中567例(0.4%)发生类风湿关节炎。
  • MHT组较对照组类风湿关节炎风险未显著升高(HR 1.12,95%CI 0.998-1.256)。
  • 使用MHT≤3年与类风湿关节炎风险升高相关(HR 1.277,95%CI 1.127-1.447)。
  • 使用雌孕激素时HR为1.24(95%CI 1.05-1.46),使用替勃龙时HR为1.33(95%CI 1.13-1.57)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This retrospective cohort study aimed to investigate the impact of menopausal hormone therapy (MHT) on the incidence of rheumatoid arthritis (RA) in postmenopausal women and to examine the effects of each specific MHT drug. METHODS: In this Korean population-based cohort study, 452,124 women aged > 40 years who consulted a healthcare provider for menopause were evaluated from January 1, 2011, to December 31, 2014. After propensity score matching, 138,991 pairs were included in the MHT and non-MHT groups. Participants were followed up until December 31, 2020. RA was defined according to the International Classification of Diseases, 10th edition, limited to seropositive RA (M05). RESULTS: RA developed in 567 (0.4 %) of the 138,424 patients in the MHT group. The RA risk in the MHT group was not significantly increased compared with that of controls (hazard ratio [HR] 1.12, 95 % confidence interval [CI] 0.998-1.256). However, MHT use for ≤ 3 years was associated with an increased risk of RA (HR 1.277, 95 % CI 1.127-1.447). When estrogen/progestogen was used, the HR was 1.24 (95 % CI 1.05-1.46), whereas when tibolone was used, the HR was 1.33 (95 % CI 1.13-1.57). CONCLUSION: The use of MHT did not show a significant impact on the development of RA in postmenopausal women. However, a subanalysis that specifically examined the duration of MHT revealed a noteworthy increase in the risk of RA during the initial 3 years of MHT use.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Yuk JS, Seo YS, Im YH, et al. Menopausal hormone therapy and risk of seropositive rheumatoid arthritis: A nationwide cohort study in Korea. Semin Arthritis Rheum. 2023. PMID: 37857046. doi:10.1016/j.semarthrit.2023.152280

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。